15-Amino Acid BMP-7 Peptide for Bone Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis, osteoarthritis, and bone defects are associated with significant side effects and high costs, and there is a need for a novel therapeutic agent that can promote bone formation without these drawbacks.
Innovation Solution
A synthetic peptide derived from BMP-7, consisting of 15 amino acid residues, is developed to promote osteoblast differentiation and bone formation, which can be synthesized at a low cost and used in pharmaceutical compositions to treat bone-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutics (estrogen, bisphosphonate agents, vitamin D agents) are used to treat osteoporosis, then bone mass can be maintained or improved, but significant side effects occur (endometrial cancer, breast cancer, thrombosis, esophagitis, high cost)
Solution Approach 1:
The patent extracts the active osteogenic component from the complex BMP-7 protein, isolating a specific 15-amino acid peptide sequence that retains bone-forming activity. This extraction allows the therapeutic effect to be achieved with a simplified molecule that lacks the harmful side effects of conventional treatments.
Solution Approach 2:
The patent employs a short peptide sequence (15 amino acids) instead of large protein molecules or long-term hormone therapy. This shorter, simpler molecular structure is more easily synthesized, has lower production costs, and can be rapidly produced as needed, replacing expensive and complex conventional therapies.
2Reliability
If conventional therapeutics are used to treat osteoporosis, then bone health can be improved, but production costs and treatment expenses are high
Solution Approach 1:
The patent uses a short 15-amino acid peptide that is significantly cheaper to synthesize than large protein molecules or complex hormone formulations. The simplified structure allows for efficient chemical synthesis and lower production costs while maintaining therapeutic efficacy.
Solution Approach 2:
The patent changes the molecular parameters from large, complex proteins to a compact 15-amino acid sequence. This parameter change (reducing molecular size and complexity) directly reduces production costs while preserving the essential osteogenic function through careful selection of the amino acid sequence.
3Productivity
If BMP-7 is used to promote bone formation, then osteoblast differentiation is enhanced, but the complexity and cost of production increase
Solution Approach 1:
The patent extracts the essential functional sequence from the full BMP-7 protein, isolating a 15-amino acid peptide that contains the osteogenic activity. This extraction reduces molecular complexity from the full protein to a minimal functional unit while maintaining bone-forming capability.
Solution Approach 2:
The patent segments the BMP-7 protein into a specific 15-amino acid sequence that preserves the osteogenic function. This segmentation creates a discrete, manageable peptide fragment that is easier to produce and administer while maintaining high productivity in promoting osteoblast differentiation.
Data Source
AI summary
Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis.